Supernus Pharmaceuticals, Inc. SUPN -1.49% (the "Company"), today announced the closing of its initial public offering of 10,000,000 of its common stock at a price of $5.00 per share. The Company's shares are listed on The NASDAQ Global Market under the trading symbol "SUPN." After underwriting discounts and commissions and estimated offering expenses, the Company received net proceeds of approximately $45.5 million.
The Company expects to use all of the net proceeds from this offering received by the Company to fund the expected commercial launch of SPN-538 and the preparation for the commercial launch of SPN-804, the continued clinical development of SPN-810 and SPN-812, the repayment of a portion of the principle of the term loans under our secured credit facility and for other general corporate purposes.
Citigroup and Piper Jaffray & Co. are acting as joint book-running managers for the offering. Cowen and Company, LLC and Stifel Nicolaus Weisel are acting as co-managers.
A copy of the final prospectus related to these securities may be obtained by contacting: Citigroup at Brooklyn Army Terminal, 140 58th Street, 8th Floor, Brooklyn, NY 11220, Attention: Prospectus Department, telephone: 1-800-831-9146 or email: email@example.com, or Piper Jaffray & Co. at 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, telephone: 1-800-747-3924 or e-mail: firstname.lastname@example.org.
A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.